Articles by CNW Group


No Image

Canopy Rivers to Report Third Quarter Fiscal Year 2020 Financial Results and Host Earnings Call

TORONTO, Jan. 24, 2020 /PRNewswire/ – Canopy Rivers Inc. (“Canopy Rivers” or the “Company”) (TSX: RIV, OTC: CNPOF), a venture capital firm specializing in cannabis, will report its third quarter fiscal year 2020 financial results before markets open on Friday, February 14, 2020. The Company’s unaudited condensed interim consolidated financial statements and management’s discussion and analysis of financial results for the nine months ended December 31, 2019 will be available on the Company’s profile on the System for Electronic Document Analysis and Retrieval (“SEDAR”) at www.sedar.com and on the Company’s website at www.canopyrivers.com/investors/financials-and-public-filings.


No Image

PharmaCielo Signs Pan-European Distribution Agreement for CBD Isolate and Broad-Spectrum CBD Oil

TORONTO and RIONEGRO, Colombia, Jan. 24, 2020 /CNW/ – PharmaCielo Ltd. (“PharmaCielo” or the “Company”) (TSXV: PCLO, OTCQX: PCLOF), the Canadian parent of Colombia’s premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., announces it has signed a three-year pan-European distribution agreement (the “Agreement”), in which the Company’s high-grade CBD isolate and broad-spectrum CBD oil will be sold to wholesalers and medicinal CPG product manufacturers through GMP certified lab owner, CBD Export Global.


No Image

Crescita Awarded Cannabis Research License from Health Canada

LAVAL, QC, Jan. 24, 2020 /PRNewswire/ – Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (“Crescita” or the “Company”), a commercial dermatology company with manufacturing capabilities and a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, diseases and their symptoms, is pleased to announce that its wholly-owned subsidiary, INTEGA Skin Sciences Inc. (“INTEGA”) has been awarded a cannabis research license (the “Research License”) by Health Canada under the Cannabis Act and Cannabis Regulations, allowing the Company to possess cannabis for the purpose of research and development (“R&D”).






No Image

Dixie Brands Reconstitutes Board of Directors

DENVER, Jan. 23, 2020 /CNW/ – Dixie Brands Inc. (“Dixie” or “the Company”) (CSE: DIXI.U), (OTCQX: DXBRF), (Frankfurt: 0QV), one of the cannabis industry’s leading consumer packaged goods (“CPG”) companies, today announced a reconstitution of its Board with the departure of long standing members, Vincent Keber and Devin Binford, and the appointment of Dan Phaure.